UniQuest, AstraZeneca collaborate on drug discovery

The collaboration fosters medical innovation by bringing together complementary skills.

30 April 2015

Pharmaceutical company AstraZeneca and UniQuesthave formed an “open innovation” program to support academic research that holds promise of new therapeutic drugs.

Dr Dean Moss, chief executive officer of UniQuest – The University of Queensland’s research commercialization company – said the agreement would give researchers access to high-quality AstraZeneca compounds to investigate human mechanisms of disease and to explore the development of novel target therapies for areas of high unmet medical need.




Leave a Reply